Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma

BRAF inhibitors revolutionised the management of melanoma patients and although resistance occurs, there is a subgroup of patients who maintain durable disease control. For those cases with durable complete response (CR) it is not clear whether it is safe to cease therapy. Here we identified 13 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Warburton, L., Meniawy, T. M., Calapre, L., Pereira, M., McEvoy, A., Ziman, M., Gray, E. S., Millward, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606504/
https://www.ncbi.nlm.nih.gov/pubmed/33139839
http://dx.doi.org/10.1038/s41598-020-75837-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606504/
https://www.ncbi.nlm.nih.gov/pubmed/33139839
http://dx.doi.org/10.1038/s41598-020-75837-5

Ejemplares similares